Hematology/ Oncology and Stem Cell Therapy最新文献_第7页

The Impact of Post-Hematopoietic Stem Cell Transplant Tyrosine Kinase Inhibitors in Philadelphia-Positive Acute Lymphoblastic Leukemia. 造血干细胞移植后酪氨酸激酶抑制剂对费城阳性急性淋巴细胞白血病的影响。

Hematology/ Oncology and Stem Cell Therapy Pub Date : 2022-12-23 DOI: 10.1016/j.hemonc.2021.07.003

Khalid Halahleh, Dalia Al Rimawi, Amal Abu Ghosh, Isra Muradi, Waleed Da'na, Mehdi Hamadani

引用次数: 2

Leucoerythroblastic PICTURE and Bone Marrow Fibrosis: Infantile Primary Myelofibrosis. 白细胞母细胞成像与骨髓纤维化:婴儿原发性骨髓纤维化。

Hematology/ Oncology and Stem Cell Therapy Pub Date : 2022-12-23 DOI: 10.1016/j.hemonc.2021.10.002

Hasan Hashem, Nazmi Kamal

引用次数: 0

Escalated Dose Donor Lymphocyte Infusion Treatment in Patients with Primary Immune Deficiencies After HSCT with Reduced-Intensity Conditioning Regimen. 加重剂量供体淋巴细胞输注治疗HSCT后原发性免疫缺陷患者的低强度调节方案。

Hematology/ Oncology and Stem Cell Therapy Pub Date : 2022-12-23 DOI: 10.1016/j.hemonc.2021.06.002

Tahani Ali, Maryam Behfar, Rashin Mohseni, Pourya Salajegheh, Maged Kheder, Faihaa Abou-Fakher, Zeynab Nikfetrat, Fahimeh Jafari, Parisa Naji, Amir Ali Hamidieh

{"title":"Escalated Dose Donor Lymphocyte Infusion Treatment in Patients with Primary Immune Deficiencies After HSCT with Reduced-Intensity Conditioning Regimen.","authors":"Tahani Ali, Maryam Behfar, Rashin Mohseni, Pourya Salajegheh, Maged Kheder, Faihaa Abou-Fakher, Zeynab Nikfetrat, Fahimeh Jafari, Parisa Naji, Amir Ali Hamidieh","doi":"10.1016/j.hemonc.2021.06.002","DOIUrl":"https://doi.org/10.1016/j.hemonc.2021.06.002","url":null,"abstract":"Objective/background: Mixed chimerism is a major concern after allogenic hematopoietic stem cell transplantation (HSCT) using a reduced-intensity conditioning (RIC) regimen in primary immunodeficiencies (PIDs). A donor lymphocyte infusion (DLI) escalating dose regimen has been developed with the aim of reducing toxicity while preserving efficacy. However, the graft-versus-host disease (GvHD) development remains the most common and adverse effect of DLI and continues to be a limiting factor in its application, especially nonmalignant diseases such as PIDs. We prospectively evaluated PID patients after HSCT using RIC in Childrens Medical Center, who were candidates for an escalating dose of DLI for MC from 2016 to 2018.Methods: With the median follow-up of 16.4 months, 12 patients (nine males and three females) with a median age of 3.72 years received DLI. The median number of DLI was 3.2 (range, 1-5), the maximum and total dose of DLIs administered per patient were 3.6 × 107 (range, 1-5) cells/kg CD3+ and 9.3 × 107 (range, 1-15) cells/kg CD3+ cells, respectively.Results: Median donor chimerism at baseline before the DLIs was 41% (range, 11-73%), patients received DLIs at a median of 105 (range, 37-230) days and 52 (range, 3-168) days after the HSCT and onset of the MC, respectively. At the final assessment, six (54.5%) patients improved after DLIs at a median of 47.3 days.Conclusion: PID patients may benefit from DLI with an escalating dose regimen, but the GvHD development remains a concern during the DLI, and the optimum dose and frequency must be standardized.","PeriodicalId":39226,"journal":{"name":"Hematology/ Oncology and Stem Cell Therapy","volume":"15 4","pages":"272-278"},"PeriodicalIF":0.0,"publicationDate":"2022-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.hemonc.2021.06.002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9254652","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 5

Lisocabtagene Maraleucel in Relapsed or Refractory Diffuse Large B Cell Lymphoma: What is the Evidence? Lisocabtagene Maraleucel治疗复发或难治性弥漫性大B细胞淋巴瘤:证据是什么?

Hematology/ Oncology and Stem Cell Therapy Pub Date : 2022-12-23 DOI: 10.1016/j.hemonc.2021.09.004

Mohamed A Kharfan-Dabaja, Farah Yassine, Muhamad Alhaj Moustafa, Madiha Iqbal, Hemant Murthy

{"title":"Lisocabtagene Maraleucel in Relapsed or Refractory Diffuse Large B Cell Lymphoma: What is the Evidence?","authors":"Mohamed A Kharfan-Dabaja, Farah Yassine, Muhamad Alhaj Moustafa, Madiha Iqbal, Hemant Murthy","doi":"10.1016/j.hemonc.2021.09.004","DOIUrl":"https://doi.org/10.1016/j.hemonc.2021.09.004","url":null,"abstract":"Lisocabtagene maraleucel (liso-cel) is an autologous CD19-directed chimeric antigen receptor (CAR) T cell product, with a CD3ζ activatory domain connected to 4-1BB costimulatory domain. Liso-cel, unlike the other two approved products-axicabtagene ciloleucel and tisagenlecleucel-is manufactured separately from CD4 and CD8 T cells and then administered as a sequential infusion of the two components at equal target doses. The approval of liso-cel was based on the results of Transcend NHL 001, a single-arm, open-label, multicenter, seamless design trial that enrolled 344 patients, of whom 269 received conforming liso-cel. The most common histology was diffuse large B cell lymphoma, not otherwise specified (DLBCL NOS; n = 137, 51%) followed by DLBCL transformed from indolent lymphomas (n = 78, 29%). Encouraging results were reported, yielding an objective response rate across all dose levels of 73% [complete remission (CR) = 53%], with an estimated duration of response at 1 year of 55% for all patients and 65% for those achieving a CR. The estimated 12-month overall survival was 58% for all patients and 86% for those achieving a CR. Cytokine release syndrome and neurological adverse events were reported in 42% and 30%, respectively. This review summarizes the evidence on the safety and effectiveness of liso-cel, resulting in its addition to the current treatment armamentarium of relapsed or refractory large B cell lymphoma.","PeriodicalId":39226,"journal":{"name":"Hematology/ Oncology and Stem Cell Therapy","volume":"15 4","pages":"168-175"},"PeriodicalIF":0.0,"publicationDate":"2022-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9084892","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 5

Comparison of Mitoxantrone-Melphalan and BEAM Conditioning Regimens in Patients with Lymphoma. 米托蒽醌-美法兰与BEAM调理方案在淋巴瘤患者中的比较。

Hematology/ Oncology and Stem Cell Therapy Pub Date : 2022-12-23 DOI: 10.1016/j.hemonc.2021.03.005

Ahmet Kursad Gunes, Istemi Serin, Ilknur Demir, Serpil Sarifakiogullari, Salih Sertac Durusoy, Dervis Murad Akkurt, Idris Ince, Gulkan Ozkan, Tahir Alper Cinli, Mustafa Pehlivan

{"title":"Comparison of Mitoxantrone-Melphalan and BEAM Conditioning Regimens in Patients with Lymphoma.","authors":"Ahmet Kursad Gunes, Istemi Serin, Ilknur Demir, Serpil Sarifakiogullari, Salih Sertac Durusoy, Dervis Murad Akkurt, Idris Ince, Gulkan Ozkan, Tahir Alper Cinli, Mustafa Pehlivan","doi":"10.1016/j.hemonc.2021.03.005","DOIUrl":"https://doi.org/10.1016/j.hemonc.2021.03.005","url":null,"abstract":"Objective/background: Lymphoma is seen as a highly treatable and curable malignancy with aggressive treatment methods. Efficacy is often limited by toxicity and many patients need alternative treatment strategies as they cannot tolerate existing high cytotoxic approaches. Our aim is to compare BEAM [carmustine (BCNU), etoposide, cytarabine (ARA-C, cytosine arabinoside), and melphalan] and mitoxantrone-melphalan (Mx-Mel) regimens utilized in our patients with a diagnosis of lymphoma who underwent autologous stem cell transplantation (ASCT), and to demonstrate that the Mx-Mel regimen has similar but less toxic results than the BEAM regimen we have been using frequently as standard conditioning regimen.Methods: A total of 101 patients with lymphoma who underwent ASCT were included in our study. The BEAM regimen included BCNU, etoposide, ARA-C, and melphalan. The Mx-Mel regimen included mitoxantrone and melphalan.Results: Of 101 patients included in the study, 60 (59.4%) received BEAM and 41 (40.6%) received Mx-Mel (40.6%) conditioning regimen. The median time to neutrophil engraftment was 10 (range: 9-20) days and 12 (range: 9-12) days in the BEAM and Mx-Mel arms, respectively; it was statistically significantly shorter in the BEAM arm (p = .001).Conclusion: This study demonstrates that the Mx-Mel regimen has similar efficacy and toxicity compared with the BEAM regimen. Although time to neutrophil engraftment was shorter in the BEAM arm, it did not result as significant transplant-related complications between the two regimens. The Mx-Mel regimen is seen as a good alternative with low toxicity and high efficacy.","PeriodicalId":39226,"journal":{"name":"Hematology/ Oncology and Stem Cell Therapy","volume":"15 4","pages":"201-207"},"PeriodicalIF":0.0,"publicationDate":"2022-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.hemonc.2021.03.005","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10512161","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Adoptive Cellular Therapy in Acute Myeloid Leukemia: Current Scope and Challenges. 急性髓性白血病的过继细胞治疗:目前的范围和挑战。

Hematology/ Oncology and Stem Cell Therapy Pub Date : 2022-12-15 DOI: 10.56875/2589-0646.1060

Sankalp Arora, Palash Asawa, Aravind Ramakrishnan, Carlos Bachier, Navneet S Majhail

{"title":"Adoptive Cellular Therapy in Acute Myeloid Leukemia: Current Scope and Challenges.","authors":"Sankalp Arora, Palash Asawa, Aravind Ramakrishnan, Carlos Bachier, Navneet S Majhail","doi":"10.56875/2589-0646.1060","DOIUrl":"https://doi.org/10.56875/2589-0646.1060","url":null,"abstract":"Adoptive cellular therapies have revolutionized the management of hematologic malignancies, particularly lymphoma and multiple myeloma. These therapies targeting disease-specific antigens, such as CD19 in lymphoma and B cell maturation antigen in multiple myeloma, are efficacious and well-tolerated compared with conventional chemotherapies. Unfortunately, their potential remains unrealized in acute myeloid leukemia (AML). This is because most targetable antigens on AML cells are also expressed on healthy myeloid hematopoietic stem cells (HSC). Therefore, targeting them results in severe myeloablative effects and pancytopenia. Several strategies have been devised to overcome this barrier, including identifying AML-specific antigens, limiting CAR-T cell persistence to prevent prolonged myeloablation, and creating AML-specific antigens through manipulating HSCs prior to allogenic transplant. In this review, we discuss these strategies and the ongoing clinical trials on adoptive cellular therapies in AML, limiting our focus to chimeric antigen receptor-T cells (CAR-T) and chimeric antigen receptor-natural killer cells (CAR-NK).","PeriodicalId":39226,"journal":{"name":"Hematology/ Oncology and Stem Cell Therapy","volume":"15 3","pages":"159-167"},"PeriodicalIF":0.0,"publicationDate":"2022-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10405868","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Allogeneic Chimeric Antigen Receptor T Cells for Hematologic Malignancies. 同种异体嵌合抗原受体T细胞用于血液恶性肿瘤。

Hematology/ Oncology and Stem Cell Therapy Pub Date : 2022-12-15 DOI: 10.56875/2589-0646.1030

Yang Yang, Xia Bi, Mia Gergis, Dongni Yi, Jingmei Hsu, Usama Gergis

引用次数: 2

Chimeric Antigen Receptor T-cell Therapy for Acute Myeloid Leukemia. 嵌合抗原受体t细胞治疗急性髓性白血病。

Hematology/ Oncology and Stem Cell Therapy Pub Date : 2022-12-15 DOI: 10.56875/2589-0646.1062

Xia Bi, Jingmei Hsu, Mia Gergis, Yang Yang, Dongni Yi, Usama Gergis

引用次数: 2

Chimeric Antigen Receptor T-cell Therapies in Lymphoma Patients with Central Nervous System Involvement. 嵌合抗原受体t细胞治疗累及中枢神经系统的淋巴瘤。

Hematology/ Oncology and Stem Cell Therapy Pub Date : 2022-12-15 DOI: 10.56875/2589-0646.1024

Dongni Yi, Mia Gergis, Ghada Elgohary, Jingmei Hsu, Yang Yang, Xia Bi, Usama Gergis

{"title":"Chimeric Antigen Receptor T-cell Therapies in Lymphoma Patients with Central Nervous System Involvement.","authors":"Dongni Yi, Mia Gergis, Ghada Elgohary, Jingmei Hsu, Yang Yang, Xia Bi, Usama Gergis","doi":"10.56875/2589-0646.1024","DOIUrl":"https://doi.org/10.56875/2589-0646.1024","url":null,"abstract":"Background and objective: CAR T-cell therapy has significantly improved the outcomes of patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL). However, most clinical trials excluded patients with central nervous system (CNS) involvement due to uncertain efficacy and safety.Material and methods: On January 1, 2022, we searched PubMed to identify all published literature associated with current commercial CAR T-cell therapies for B-NHL, including tisagenlecleucel (tisa-cel), axicabtagene ciloleucel (axi-cel), brexucabtagene autoleucel (brexu-cel), and lisocabtagene maraleucel (liso-cel). Studies that involved patients with either primary or secondary CNS lymphoma, and evaluated response rate, adverse events (AEs), or survival were included and summarized.Result: Herein, we summarize the results of 11 studies qualified for our inclusion criteria, reporting 58 lymphoma patients with CNS Involvement with 44 evaluable for clinical response, 25 for immune effector cell-associated neurotoxicity syndrome (ICANS) and 48 for Cytokine release syndrome (CRS). Objective response was achieved in 62% (16/26) of patients, and CR was achieved in 52% (23/44) of patients. Forty-four percent (11/25) developed ICANS, and 35% (17/48) developed severe ICANS (grade≥3). CRS was reported in 63% (15/24) of patients, while severe CRS (grade≥3) was reported in 7% (3/42) of patients.Conclusion: Based on our PubMed literature review, we conclude that CAR T-cell therapy may benefit patients with CNS lymphoma with promising response rates and acceptable AE. However, definite conclusions cannot be drawn until data with a larger sample size is available.","PeriodicalId":39226,"journal":{"name":"Hematology/ Oncology and Stem Cell Therapy","volume":"15 3","pages":"66-72"},"PeriodicalIF":0.0,"publicationDate":"2022-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10405867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Chimeric Antigen Receptor T Cell Therapy For Solid Tumors. 嵌合抗原受体T细胞治疗实体瘤。

Hematology/ Oncology and Stem Cell Therapy Pub Date : 2022-12-15 DOI: 10.56875/2589-0646.1028

Jingmei Hsu, Yang Yang, Mia Gergis, Xia Bi, Dongni Yi, Usama Gergis

引用次数: 0